v3.26.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2026
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

Note 6. Commitments and Contingencies

The Company had unfunded debt commitments to various revolving and delayed-draw term loans. The total amount of these unfunded commitments as of March 31, 2026 and December 31, 2025 was $22,528 and $21,083, respectively, comprised of the following:

 

 

March 31, 2026

 

 

December 31, 2025

 

Treace Medical Concepts, Inc.

 

$

6,229

 

 

$

6,229

 

Refocus Management Services, LLC

 

 

2,486

 

 

 

 

Ardelyx, Inc.

 

 

2,387

 

 

 

2,387

 

DeepIntent, Inc.

 

 

2,352

 

 

 

2,211

 

SunMed Receivables I, LLC

 

 

1,457

 

 

 

1,457

 

OIS Management Services, LLC

 

 

1,296

 

 

 

1,296

 

AAH Topco, LLC

 

 

1,035

 

 

 

1,381

 

Western Veterinary Partners LLC

 

 

827

 

 

 

1,740

 

Pinnacle Fertility, Inc.

 

 

744

 

 

 

744

 

Montefiore Nyack Hospital

 

 

725

 

 

 

 

NS and Associates LLC

 

 

457

 

 

 

457

 

CVAUSA Management, LLC

 

 

429

 

 

 

445

 

Arcutis Biotherapeutics, Inc.

 

 

419

 

 

 

837

 

Southern Orthodontic Partners Management, LLC

 

 

359

 

 

 

756

 

Eyesouth Eye Care Holdco LLC

 

 

335

 

 

 

447

 

Metro West Ambulance Service, Inc.

 

 

293

 

 

 

 

United Digestive MSO Parent, LLC

 

 

193

 

 

 

192

 

Foundation Consumer Brands, LLC

 

 

171

 

 

 

171

 

SunMed Group Holdings, LLC

 

 

132

 

 

 

132

 

Exactcare Parent, Inc.

 

 

102

 

 

 

102

 

Medrina, LLC

 

 

100

 

 

 

99

 

Total Commitments

 

$

22,528

 

 

$

21,083

 

 

The credit agreements governing the above loan commitments contain customary lending provisions and/or are subject to the respective portfolio company’s achievement of certain milestones that allow relief to the Company from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. Since these commitments may expire without being drawn upon, unfunded

commitments do not necessarily represent future cash requirements or future earning assets for the Company. As of March 31, 2026 and December 31, 2025, the Company had sufficient cash available and/or liquid securities available to fund its commitments and had reviewed them for any appropriate fair value adjustment.

In the normal course of our business, we invest or trade in various financial instruments and may enter into various investment activities with off-balance sheet risk, which may include forward foreign currency contracts. Generally, these financial instruments represent future commitments to purchase or sell other financial instruments at specific terms at future dates. These financial instruments contain varying degrees of off-balance sheet risk whereby changes in the market value or our satisfaction of the obligations may exceed the amount recognized in our Consolidated Statements of Assets and Liabilities. As of March 31, 2026 and December 31, 2025, we held no such contracts.

From time to time, the Company may become a party to certain legal proceedings incidental to the normal course of its business. As of March 31, 2026 and December 31, 2025, management is not aware of any material pending or threatened litigation that would require accounting recognition or financial statement disclosure.